Andelyn Biosciences Sets Up US–APAC Manufacturing Bridge Through ENCell Partnership

New updates have been reported about Andelyn Biosciences.

Andelyn Biosciences has signed a strategic collaboration agreement with Korea-based CDMO ENCell to create a U.S.–Asia-Pacific manufacturing corridor for cell and gene therapies, a move that materially extends Andelyn’s geographic reach and service capability. The alliance connects Andelyn’s Columbus, Ohio cGMP viral vector operations with ENCell’s APAC clinical and manufacturing network, enabling clients to run regional clinical trials with in-country production while simplifying regulatory and logistical complexity.

By offering a coordinated “dual hemisphere” workflow, Andelyn can now support global programs from early development through commercial scale with reduced lead times and more resilient supply chains tailored to local patient populations. CEO Wade Macedone framed the partnership as a core step in building an international manufacturing network that can deliver next-generation gene therapies at scale, while ENCell’s leadership highlighted the combination of Andelyn’s AAV and viral vector expertise with APAC clinical execution as a driver for faster, more scalable global trials. Strategically, the deal positions Andelyn as a more competitive, full-service CDMO for sponsors targeting multi-region studies, potentially increasing program volume across its 2,000-liter suspension and adherent platforms and reinforcing its role in over 80 global clinical trials to date.